Pharma BD Deal Intelligence
The $2.65B Roxane acquisition vaults Hikma into the top six US generics players by revenue and adds 88 differentiated products plus a 57-Para-IV ANDA pipeline.
The price renegotiation reflected sector-wide pricing pressure on US generics, though the strategic logic of scale plus complex-formulation depth remained…
Hikma cut its cash payment to Boehringer by $535M after Roxane's 2015 revenue underperformed, with higher wholesaler rebates eroding net selling prices on…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Hikma agreed to acquire Roxane Laboratories from Boehringer Ingelheim for $1.18B cash plus 40M new Hikma shares (~$2.6B aggregate) plus up to $125M contingent payments. Closed February 29, 2016 with cash portion reduced by $535M to ~$647M due to lower 2015 revenue. Made Hikma the sixth-largest US generics company.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Hikma Pharmaceuticals PLC / Boehringer Ingelheim (Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc.) (this deal) | 2015 | $2.6B | 29 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
← Browse all deals · How we score deals
More: 2015 deals · Neurology deals